Not logged in
  Home   Markets   Shares   Funds   Portfolio   Toolbox   Charting   Alerts   Directory   
 Admin   

Wed 13 Jul 2011, 17:00 BIO - BioScience Brands Limited - Trading statement
BIO
BIO                                                                             
BIO - BioScience Brands Limited - Trading statement                             
BioScience Brands Limited                                                       
Registration number 2005/005805/07                                              
Incorporated in the Republic of South Africa                                    
Share code: BIO                                                                 
ISIN code: ZAE000115036                                                         
TRADING STATEMENT                                                               
In terms of the Listings Requirements of the JSE Limited ("the JSE"), listed    
companies are required to publish a trading statement as soon as they become    
reasonably certain that the financial results for the next period to be reported
on will be more than 20% different from those of the previous corresponding     
period or from a profit forecast previously provided to the market in relation  
to such period.                                                                 
The loss per share and headline loss per share for the year ended 30 June 2011  
are expected to increase by more than 20% compared to the loss per share and    
headline loss per share of 0.26 cents as reported for the previous financial    
year.                                                                           
Whilst BioScience Brands Limited ("BioScience") has affected the relocation of  
its head-office and began outsourcing the daily operations to Akacia Healthcare 
(Pty) Ltd ("Akacia") in Isando from 1 April 2011, the reduction in overhead     
costs has only fully impacted since 1 May 2011. During the last financial year, 
BioScience has continued to trade in a tough consumer environment where the     
discretionary spend on complementary health and nutritional products remains    
depressed. In addition and as announced previously, the financial results for   
the year includes the impairment of the Phyto Nova brand of R6.5m.              
The financial information on which this trading statement is based has not been 
reviewed or reported on by the Group`s external auditors.                       
The publication of the results is expected on or about 16 September 2011.       
Johannesburg                                                                    
13 July 2011                                                                    
Designated Advisor                                                              
PricewaterhouseCoopers Corporate Finance (Pty) Ltd                              
Date: 13/07/2011 17:00:01 Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.                                          
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
Other Profile Group sites: FundsData Online (unit trust data)  |  Profile Group corporate site
Terms of Use |  Privacy Policy |  PAIA manual |  FAQs/Help |  Site Map |  © Copyright Reserved 2026  ]
  


Powered by ProfileData

Profile Mobile App Google Play Store Apple App Store


Follow us on: